1,028 Spam-Free Article(s) Found
Symbol Name Last Close Mkt Cap DailyStocks'
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Wednesday’s Close
MRK Merck & Company, Inc. $70.42 $187.28B N/A
Article Searches
Old Dominion (ODFL) to Report Q4 Earnings: What's in Store? http://www.zacks.com/stock/news/742534/old-dominion-odfl-to-report-q4-earnings-whats-in-store?cid=CS-ZC-FT-analyst_blog|earnings_preview-742534 Jan 31, 2020 - Old Dominion's (ODFL) fourth-quarter 2019 results will likely reflect unfavorable impact of a soft freight environment.
3 Cancer Treatment Stocks to Buy Right Now https://www.fool.com/investing/2020/01/28/3-cancer-treatment-stocks-to-buy-right-now.aspx?source=iedfolrf0000001 Jan 28, 2020 - These three companies are innovators in the development of cancer drugs, and they can also make you a lot of money.
FDA Approves Merck's Dificid for Infections in Children https://www.fool.com/news/2020/01/27/fda-approves-mercks-dificid-for-infections-in-chil.aspx?source=iedfolrf0000001 Jan 27, 2020 - The approval includes a new oral suspension version of the drug.
Top Stock Analyst Reports for Merck, Broadcom & Sanofi http://www.zacks.com/research-daily/734833/top-stock-analyst-reports-for-merck-broadcom-sanofi?cid=CS-ZC-FT-research_daily-734833 Jan 27, 2020 - Top Stock Analyst Reports for Merck, Broadcom & Sanofi
Roche Submits Application for Tecentriq-Avastin Combo in HCC http://www.zacks.com/stock/news/734523/roche-submits-application-for-tecentriq-avastin-combo-in-hcc?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-734523 Jan 27, 2020 - Roche (RHHBY) submits sBLA for the label expansion of the Tecentriq-Avastin combo to treat HCC patients who have not received prior systemic therapy.
What Lies Ahead for Healthcare ETFs in Q4 Earnings? http://www.zacks.com/stock/news/731805/what-lies-ahead-for-healthcare-etfs-in-q4-earnings?cid=CS-ZC-FT-etf_news_and_commentary-731805 Jan 24, 2020 - With earnings surprise in the cards, the healthcare sector is expected to witness substantial earnings growth of 4.4% in the fourth quarter, suggesting some room for potential upside for healthcare ETFs.
Will Pfizer's (PFE) BioPharma Unit Boost Its Q4 Earnings? http://www.zacks.com/stock/news/731666/will-pfizers-pfe-biopharma-unit-boost-its-q4-earnings?cid=CS-ZC-FT-analyst_blog|earnings_preview-731666 Jan 24, 2020 - Higher sales of Pfizer's (PFE) key brands, Eliquis, Xeljanz, Ibrance in the Biopharma segment are likely to have made up for lower sales in the Upjohn group.
Pharma Stock Roundup: J&J's Mixed Q4, Roche & Novartis' New Drugs Approval in EU http://www.zacks.com/stock/news/731626/pharma-stock-roundup-jjs-mixed-q4-roche-novartis-new-drugs-approval-in-eu?cid=CS-ZC-FT-analyst_blog|stock_roundup-731626 Jan 24, 2020 - J&J (JNJ) announces mixed Q4 results. Roche's (RHHBY) lymphoma drug, Polivy and Novartis' (NVS) Mayzent for secondary progressive multiple sclerosis (SPMS) get approval in Europe.
5 Big Drug/Biotech Stocks Set to Trump Q4 Earnings Estimates http://www.zacks.com/stock/news/729100/5-big-drug-biotech-stocks-set-to-trump-q4-earnings-estimates?cid=CS-ZC-FT-earnings_esp-729100 Jan 22, 2020 - Let us take a look at some drug/biotech stocks that are poised to beat on earnings in the fourth quarter.
Horizon Therapeutics Gets FDA Approval for Eye Drug Tepezza http://www.zacks.com/stock/news/729180/horizon-therapeutics-gets-fda-approval-for-eye-drug-tepezza?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-729180 Jan 22, 2020 - Horizon Therapeutics' (HZNP) Tepezza becomes the first FDA-approved therapy for treating thyroid eye disease, a rare, autoimmune disease. Stock up.

Pages: 12345678...103

<<<Page 3>